Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567926 | 0.81 | PLAU (0.47) | MAOAMAOBCYP19A1 | |
| SCHEMBL17974767 | 0.81 | PLAU (0.47) | MAOAMAOBCYP19A1 | |
| SCHEMBL17974765 | 0.81 | PLAU (0.47) | MAOAMAOBCYP19A1 | |
| SCHEMBL2215028 | 0.73 | CYP19A1 (0.46) | CES1CYP19A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL11554985 | 0.73 | CYP2A6 (0.50) | CYP2A6MAOAMAOBCES1HTR7 | |
| SCHEMBL7712799 | 0.73 | CYP2A6 (0.50) | CYP2A6MAOAMAOBCES1HTR7 | |
| SCHEMBL10568326 | 0.73 | PLAU (0.60) | CYP2A6MAOAMAOBCES1HTR7 | |
| SCHEMBL10568813 | 0.73 | MAOA (0.50) | CYP2A6MAOAMAOBCES1HTR7 | |
| SCHEMBL11742887 | 0.71 | TSHR (0.41) | ALDH1A1 | |
| SCHEMBL5500714 | 0.70 | IDO1 (0.38) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0167256-B1 | NORTRIPTYLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, CONJUGATES THEREOF TO ANTIGENIC PROTEINS AND ENZYMES, ANTIBODIES THERETO, AND RELATED ASSAY METHODS | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4814335-A | Antiviral compounds | BIOMEASURE, INCORPORATED (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0296848-A1 | Biological response modifiers, their production, and their use in therapy or in prophylaxis | BIOMEASURE, INC. (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0167256-A1 | Nortriptyline derivatives, processes for their preparation, conjugates thereof to antigenic proteins and enzymes, antibodies thereto, and related assay methods | SYNTEX (U.S.A.) INC. (US) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | CYP2A6 3315/4885MAOA 3572/4885MAOB 3249/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | CYP2A6 3315/4885MAOA 3572/4885MAOB 3249/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | CYP2A6 3328/4885MAOA 3554/4885MAOB 3266/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | CYP2A6 3024/4885MAOA 3333/4885MAOB 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.